NA Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

North America fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Dominican Republic, Jamaica, Panama) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America fibrotic diseases treatment market are:

Rising prevalence of fibrotic diseases

Technological advancement in the treatment of fibrosis diseases

Market Players:

Some of the key market players in the North America fibrotic diseases treatment market are listed below:

Genentech, Inc.

Boehringer Ingelheim International GmbH

AbbVie Inc.

Bristol-Myers Squibb Company

BellBrook Labs

Enveda Biosciences

Gilead Sciences, Inc.

Verona Pharma plc

Alpine Immune Sciences

Intercept Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Accord Healthcare

Camber Pharmaceuticals, Inc

1 INTRODUCTION 33

1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53

5 EPIDEMIOLOGY 54

5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55

6 INDUSTRY INSIGHTS 56

6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58

7 MERGERS AND ACQUISITIONS 60

7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60

8 PIPELINE ANALYSIS 61

8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61

9 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62

9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63

10 MARKET OVERVIEW 64

10.1 DRIVERS 66
- 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
- 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
- 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
- 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
- 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
- 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
- 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
- 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
- 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69

11 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70

11.1 OVERVIEW 71
11.2 MEDICATION 73
- 11.2.1 INTEDANIB (OFEV) 74
- 11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76

12 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77

12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84

13 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85

13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91

14 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92

14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97

15 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98

15.1 NORTH AMERICA 99
- 15.1.1 U.S. 105
- 15.1.2 CANADA 107
- 15.1.3 MEXICO 109
- 15.1.4 DOMINICAN REPUBLIC 111
- 15.1.5 JAMAICA 113
- 15.1.6 PANAMA 115

16 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 117

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 117

17 SWOT ANALYSIS 118

18 COMPANY PROFILE 119

18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 119
- 18.1.1 COMPANY SNAPSHOT 119
- 18.1.2 REVENUE ANALYSIS 119
- 18.1.3 COMPANY SHARE ANALYSIS 120
- 18.1.4 PRODUCT PORTFOLIO 120
- 18.1.5 RECENT DEVELOPMENTS 120
18.2 GENENTECH, INC. 121
- 18.2.1 COMPANY SNAPSHOT 121
- 18.2.2 COMPANY SHARE ANALYSIS 121
- 18.2.3 PRODUCT PORTFOLIO 122
- 18.2.4 RECENT DEVELOPMENTS 122
18.3 SANDOZ INTERNATIONAL GMBH 123
- 18.3.1 COMPANY SNAPSHOT 123
- 18.3.2 COMPANY SHARE ANALYSIS 123
- 18.3.3 PRODUCT PORTFOLIO 124
- 18.3.4 RECENT DEVELOPMENTS 124
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 125
- 18.4.1 COMPANY SNAPSHOT 125
- 18.4.2 REVENUE ANALYSIS 125
- 18.4.3 COMPANY SHARE ANALYSIS 126
- 18.4.4 PRODUCT PORTFOLIO 126
- 18.4.5 RECENT DEVELOPMENTS 126
18.5 ACCORD HEALTHCARE U.S. 127
- 18.5.1 COMPANY SNAPSHOT 127
- 18.5.2 COMPANY SHARE ANALYSIS 127
- 18.5.3 PRODUCT PORTFOLIO 128
- 18.5.4 RECENT DEVELOPMENTS 128
18.6 ABBVIE INC. 129
- 18.6.1 COMPANY SNAPSHOT 129
- 18.6.2 REVENUE ANALYSIS 129
- 18.6.3 PRODUCT PORTFOLIO 130
- 18.6.4 RECENT DEVELOPMENTS 130
18.7 ALPINE IMMUNE SCIENCES 131
- 18.7.1 COMPANY SNAPSHOT 131
- 18.7.2 REVENUE ANALYSIS 131
- 18.7.3 PRODUCT PORTFOLIO 132
- 18.7.4 RECENT DEVELOPMENTS 132
18.8 BELLBROOK LABS 133
- 18.8.1 COMPANY SNAPSHOT 133
- 18.8.2 PRODUCT PORTFOLIO 133
- 18.8.3 RECENT DEVELOPMENTS 133
18.9 BIOMX 134
- 18.9.1 COMPANY SNAPSHOT 134
- 18.9.2 REVENUE ANALYSIS 134
- 18.9.3 PRODUCT PORTFOLIO 135
- 18.9.4 RECENT DEVELOPMENTS 135
18.10 BRISTOL-MYERS SQUIBB COMPANY 136
- 18.10.1 COMPANY SNAPSHOT 136
- 18.10.2 REVENUE ANALYSIS 136
- 18.10.3 PRODUCT PORTFOLIO 137
- 18.10.4 RECENT DEVELOPMENTS 137
18.11 CAMBER PHARMACEUTICALS, INC. 138
- 18.11.1 COMPANY SNAPSHOT 138
- 18.11.2 PRODUCT PORTFOLIO 138
- 18.11.3 RECENT DEVELOPMENTS 138
18.12 ENVEDA 139
- 18.12.1 COMPANY SNAPSHOT 139
- 18.12.2 PRODUCT PORTFOLIO 139
- 18.12.3 RECENT DEVELOPMENTS 139
18.13 GILEAD SCIENCES, INC. 140
- 18.13.1 COMPANY SNAPSHOT 140
- 18.13.2 REVENUE ANALYSIS 140
- 18.13.3 PRODUCT PORTFOLIO 141
- 18.13.4 RECENT DEVELOPMENTS 141
18.14 INTERCEPT PHARMACEUTICALS, INC. 142
- 18.14.1 COMPANY SNAPSHOT 142
- 18.14.2 REVENUE ANALYSIS 142
- 18.14.3 PRODUCT PORTFOLIO 143
- 18.14.4 RECENT DEVELOPMENTS 143
18.15 KITHER BIOTECH S.R.L. 144
- 18.15.1 COMPANY SNAPSHOT 144
- 18.15.2 PRODUCT PORTFOLIO 144
- 18.15.3 RECENT DEVELOPMENTS 144
18.16 PHARMAXIS LTD 145
- 18.16.1 COMPANY SNAPSHOT 145
- 18.16.2 REVENUE ANALYSIS 145
- 18.16.3 PRODUCT PORTFOLIO 146
- 18.16.4 RECENT DEVELOPMENTS 146
18.17 REDX PHARMA PLC. 147
- 18.17.1 COMPANY SNAPSHOT 147
- 18.17.2 REVENUE ANALYSIS 147
- 18.17.3 PRODUCT PORTFOLIO 148
- 18.17.4 RECENT DEVELOPMENTS 148
18.18 VERONA PHARMA PLC 149
- 18.18.1 COMPANY SNAPSHOT 149
- 18.18.2 REVENUE ANALYSIS 149
- 18.18.3 PRODUCT PORTFOLIO 150
- 18.18.4 RECENT DEVELOPMENTS 150

19 QUESTIONNAIRE 151

20 RELATED REPORTS 154

LIST OF TABLES

TABLE 1 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 44
TABLE 2 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 56
TABLE 3 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 57
TABLE 4 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 57
TABLE 5 NORTH AMERICA ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
TABLE 6 NORTH AMERICA OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 7 NORTH AMERICA OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 8 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 63
TABLE 9 NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 10 NORTH AMERICA HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 11 NORTH AMERICA RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 12 NORTH AMERICA CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 13 NORTH AMERICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 14 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 71
TABLE 15 NORTH AMERICA HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 16 NORTH AMERICA SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 17 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 18 NORTH AMERICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 19 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 78
TABLE 20 NORTH AMERICA HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 21 NORTH AMERICA RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 22 NORTH AMERICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 23 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 86
TABLE 24 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 86
TABLE 25 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 86
TABLE 26 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 86
TABLE 27 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 87
TABLE 28 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 87
TABLE 29 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
TABLE 30 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 87
TABLE 31 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 88
TABLE 32 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 88
TABLE 33 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 88
TABLE 34 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 88
TABLE 35 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 89
TABLE 36 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 89
TABLE 37 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 89
TABLE 38 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 90
TABLE 39 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 90
TABLE 40 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 90
TABLE 41 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 90
TABLE 42 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 91
TABLE 43 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 91
TABLE 44 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 91
TABLE 45 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 92
TABLE 46 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 92
TABLE 47 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 92
TABLE 48 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 92
TABLE 49 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 93
TABLE 50 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 93
TABLE 51 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 93
TABLE 52 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 94
TABLE 53 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 94
TABLE 54 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 94
TABLE 55 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 94
TABLE 56 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 95
TABLE 57 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 95
TABLE 58 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 59 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 96
TABLE 60 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 96
TABLE 61 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 96
TABLE 62 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 96
TABLE 63 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 97
TABLE 64 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 65 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 66 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 98
TABLE 67 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 98
TABLE 68 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 98
TABLE 69 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 98
TABLE 70 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 99
TABLE 71 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 72 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99

LIST OF FIGURES

FIGURE 1 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 19
FIGURE 2 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: DATA TRIANGULATION 22
FIGURE 3 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: DROC ANALYSIS 23
FIGURE 4 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 24
FIGURE 5 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 24
FIGURE 6 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 26
FIGURE 7 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: DBMR MARKET POSITION GRID 27
FIGURE 8 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: MARKET END USER COVERAGE GRID 28
FIGURE 9 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET : VENDOR SHARE ANALYSIS 29
FIGURE 10 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 32
FIGURE 11 RISING PREVALENCE OF FIBROTIC DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET GROWTH IN THE FORECAST PERIOD 33
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET IN 2023 & 2030 33
FIGURE 13 PATIENT FLOW DIAGRAM 41
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET 47
FIGURE 15 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2022 53
FIGURE 16 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2023-2030 (USD THOUSAND) 54
FIGURE 17 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT CAGR (2023-2030) 54
FIGURE 18 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT LIFELINE CURVE 55
FIGURE 19 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2022 60
FIGURE 20 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND) 61
FIGURE 21 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, CAGR (2023-2030) 61
FIGURE 22 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE 62
FIGURE 23 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2022 68
FIGURE 24 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 69
FIGURE 25 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, CAGR (2023-2030) 69
FIGURE 26 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, LIFELINE CURVE 70
FIGURE 27 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 75
FIGURE 28 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 76
FIGURE 29 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 76
FIGURE 30 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 77
FIGURE 31 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 82
FIGURE 32 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 83
FIGURE 33 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 83
FIGURE 34 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 84
FIGURE 35 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 84
FIGURE 36 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 99